KALY Confirms Analyst Report On Cannabis Extract Biopharm Strategy Scheduled For Next Week
August 23 2019 - 02:14PM
InvestorsHub NewsWire
KALY Confirms Analyst Report On
Cannabis Extract Biopharm Strategy Scheduled For Next Week
Dallas, TX --
August 23, 2019 -- InvestorsHub NewsWire -- Kali-Extracts, Inc.
(Kali, Inc. dba/Kali-Extracts, Inc.) (USOTC:
KALY) (“KALY”) today confirmed the publication of an analyst
report covering the company’s overall cannabis extract
biopharmaceutical strategy is scheduled for next week on Wednesday,
August 28, 2019. After making a strategic acquisition
in Q4 2018 of a business with a U.S. Patented Cannabis Extraction
Process, KALY has just posted its 2019 YTD financials
reporting 250% revenue growth. The company has also this week
filed for a new patent for a CBD Formulation
for the treatment of Chronic Obstructive Pulmonary Disease
(COPD). The CBD Formulation brand name is RespRx (www.RespRx). In light of the
recentt updates, ongoing analyst coverage will be updated with a
new report scheduled for publication on Wednesday next
week.
To learn more
about the company visit https://www.kali-extracts.com/
This press
release contains forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section
21E of the Securities Exchange Act of 1934, as amended (the
"Exchange Act"), and as such, may involve risks and uncertainties.
These forward looking statements relate to, amongst other things,
current expectation of the business environment in which the
company operates, potential future performance, projections of
future performance and the perceived opportunities in the market.
The company's actual performance, results and achievements may
differ materially from the expressed or implied in such
forward-looking statements as a result of a wide range of
factors.
CONTACT:
Frederick Ferri
ir@kali-extracts.com
(214)
210-0459
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Feb 2024 to Mar 2024
Kali (CE) (USOTC:KALY)
Historical Stock Chart
From Mar 2023 to Mar 2024